Literature DB >> 9857357

Current status of HBV vaccine escape variants--a mathematical model of their epidemiology.

J N Wilson1, D J Nokes, W F Carman.   

Abstract

We present a deterministic model of the possible emergence of a vaccine escape variant of hepatitis B virus (HBV). The model identifies the key unknowns determining this process: the protection afforded by the current vaccines against particular HBV variants; the infectiousness of these variants; and the current prevalence of individuals infectious with the variants (each factor relative to wild-type). By making pessimistic assumptions about these unknowns we show that even a highly infectious variant, under a vaccine programme that affords no protection against the variant, would still take decades to emerge. Thus the current low prevalence of variants is not evidence for the cross-reactivity of the current vaccines or for a lack of infectiousness in the variants. As any vaccine failure will be inapparent for decades it may be sensible to recommend vaccine modifications now rather than later.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9857357     DOI: 10.1046/j.1365-2893.1998.0050s2025.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  12 in total

1.  The evolutionary epidemiology of vaccination.

Authors:  Sylvain Gandon; Troy Day
Journal:  J R Soc Interface       Date:  2007-10-22       Impact factor: 4.118

2.  Stability of differential susceptibility and infectivity epidemic models.

Authors:  B Bonzi; A A Fall; A Iggidr; G Sallet
Journal:  J Math Biol       Date:  2010-02-11       Impact factor: 2.259

3.  Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited.

Authors:  Jennifer Leong; Derek Lin; Mindie H Nguyen
Journal:  World J Clin Cases       Date:  2016-03-16       Impact factor: 1.337

4.  Ultradeep Sequencing for Detection of Quasispecies Variants in the Major Hydrophilic Region of Hepatitis B Virus in Indonesian Patients.

Authors:  Laura Navika Yamani; Yoshihiko Yano; Takako Utsumi; Hadi Wandono; Doddy Widjanarko; Ari Triantanoe; Widya Wasityastuti; Yujiao Liang; Rina Okada; Toshihito Tanahashi; Yoshiki Murakami; Takeshi Azuma; Maria Inge Lusida; Yoshitake Hayashi
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

5.  Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation.

Authors:  Karen Kwei; Xiaoli Tang; Anna S Lok; Camille Sureau; Tamako Garcia; Jisu Li; Jack Wands; Shuping Tong
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

6.  Detection of S-HBsAg Mutations in Patients with Hematologic Malignancies.

Authors:  Maria V Konopleva; Maxim S Belenikin; Andrei V Shanko; Alexey I Bazhenov; Sergei A Kiryanov; Tatyana A Tupoleva; Maria V Sokolova; Alexander V Pronin; Tatyana A Semenenko; Anatoly P Suslov
Journal:  Diagnostics (Basel)       Date:  2021-05-27

7.  A model to estimate effects of SNPs on host susceptibility and infectivity for an endemic infectious disease.

Authors:  Floor Biemans; Mart C M de Jong; Piter Bijma
Journal:  Genet Sel Evol       Date:  2017-06-30       Impact factor: 4.297

Review 8.  Paradoxical HBsAg and anti-HBs coexistence among Chronic HBV Infections: Causes and Consequences.

Authors:  Xinyi Jiang; Le Chang; Ying Yan; Lunan Wang
Journal:  Int J Biol Sci       Date:  2021-03-11       Impact factor: 6.580

9.  Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.

Authors:  Maria V Konopleva; Vera N Borisova; Maria V Sokolova; Tatyana A Semenenko; Anatoly P Suslov
Journal:  Vaccines (Basel)       Date:  2022-02-03

10.  Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.

Authors:  Mark H Einstein; Peter Takacs; Archana Chatterjee; Rhoda S Sperling; Nahida Chakhtoura; Mark M Blatter; Jacob Lalezari; Marie-Pierre David; Lan Lin; Frank Struyf; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.